Lund, Sweden — 18 December 2020 — On 15 December 2020, the subscription period in Camurus AB’s (publ) (“Camurus”) subscription warrant program 2017/2020 ended. In total, 598,332 shares were subscribed for at a subscription price of SEK 153.90 per share. Through the exercise of the subscription warrants Camurus receives SEK 92,083,295.
A number of employees and senior executives of Camurus, including the company’s CEO and CFO, have sold existing shares to finance the subscription of new shares and taxes related to the transaction. As a result of the transactions, the total shareholdings of the senior executives of Camurus has increased by 1.1%.
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.
The information was submitted for publication on 18 December 2020 at 7:00 AM CET.